Moderna Plans Big R&D Cut As Profitability Guidance Pushed Out
FDA Pushes Back On mRNA-4157 Accelerated Approval
The biotech saw its shares plunge more than 12% after an R&D day, where it announced it would push a breakeven target from 2026 to 2028.
The biotech saw its shares plunge more than 12% after an R&D day, where it announced it would push a breakeven target from 2026 to 2028.